IQVIA (NYSE:IQV) Insider Bhavik Patel Sells 1,855 Shares of Stock

IQVIA Holdings Inc. (NYSE:IQV) insider Bhavik Patel sold 1,855 shares of IQVIA stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $235.27, for a total value of $436,425.85. Following the completion of the sale, the insider directly owned 1,348 shares in the company, valued at $317,143.96. This trade represents a 57.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

IQVIA Stock Performance

IQVIA stock opened at $228.18 on Wednesday. The company’s 50-day moving average price is $197.37 and its 200-day moving average price is $186.67. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18. The company has a market cap of $37.56 billion, a PE ratio of 28.31, a price-to-earnings-growth ratio of 1.97 and a beta of 1.18. IQVIA Holdings Inc. has a twelve month low of $154.50 and a twelve month high of $251.36.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The business had revenue of $4.37 billion for the quarter, compared to analysts’ expectations of $4.30 billion. During the same quarter in the previous year, the business posted $2.81 earnings per share. The business’s revenue was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, equities research analysts forecast that IQVIA Holdings Inc. will post 11.61 EPS for the current fiscal year.

IQVIA declared that its Board of Directors has approved a stock repurchase plan on Thursday, May 7th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s management believes its stock is undervalued.

More IQVIA News

Here are the key news stories impacting IQVIA this week:

• Positive Sentiment: IQVIA reported second-quarter EPS of $3.15, above the $3.03 consensus estimate, while revenue of $4.37 billion also exceeded expectations. Revenue increased 8.7% year over year, and full-year 2026 EPS guidance was set at $12.80–$13.00. Why IQVIA Stock Jumped 13% in a Week and Whether the Gains Can Last
• Positive Sentiment: Record bookings and a sizable backlog point to continued demand for IQVIA’s clinical research, data and technology services. Investors are focused on the company’s ability to convert that backlog into revenue and earnings. The Backlog Tells the Real Story: Inside IQVIA’s Blowout Q2
• Positive Sentiment: IQVIA and Medera announced a collaboration aimed at advancing cardiac gene therapy and human-based drug discovery. The partnership could strengthen IQVIA’s position in specialized clinical development and data-driven research, though financial benefits are likely longer term. IQVIA and Medera to Advance Cardiac Gene Therapy and Human-Based Drug Discovery
• Neutral Sentiment: Analyst commentary remains broadly constructive, with a consensus “Moderate Buy” rating and an average price target of $241.88. However, analysts continue to emphasize execution and backlog conversion after the recent rally. 5 Insightful Analyst Questions From IQVIA’s Q2 Earnings Call
• Negative Sentiment: Insiders have recently sold shares, including W. Richard Staub’s sale of 5,500 shares for approximately $1.28 million and Bhavik Patel’s sale of 1,855 shares for about $436,000. These transactions reduce insider ownership and may weigh on sentiment, although they do not necessarily indicate deteriorating business conditions. Insider Selling: IQVIA Insider Sells $1,279,740 in Stock
• Negative Sentiment: IQVIA’s debt-to-equity ratio of 2.18 and current ratio of 0.71 highlight leverage and liquidity risks. The company’s proprietary data platform and clinical research growth remain attractive, but investors may require continued earnings execution to justify its valuation. Is IQVIA Stock a Buy as Growth Improves but High Leverage Persists?

Analyst Ratings Changes

Several research analysts recently commented on IQV shares. Deutsche Bank Aktiengesellschaft set a $240.00 price objective on shares of IQVIA in a research note on Thursday, July 9th. Stifel Nicolaus upped their price objective on shares of IQVIA from $220.00 to $276.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. Evercore reiterated an “outperform” rating and issued a $185.00 target price on shares of IQVIA in a research note on Wednesday, April 8th. Barclays reaffirmed an “overweight” rating on shares of IQVIA in a report on Tuesday, July 28th. Finally, Morgan Stanley reissued an “equal weight” rating and issued a $200.00 target price (down from $225.00) on shares of IQVIA in a research report on Wednesday, June 17th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, IQVIA presently has an average rating of “Moderate Buy” and a consensus target price of $241.88.

Institutional Investors Weigh In On IQVIA

Several institutional investors have recently bought and sold shares of the company. Ameliora Wealth Management Ltd. acquired a new position in IQVIA during the fourth quarter worth about $25,000. International Assets Investment Management LLC acquired a new position in shares of IQVIA during the 4th quarter worth approximately $27,000. Gilpin Wealth Management LLC acquired a new stake in shares of IQVIA in the fourth quarter valued at approximately $27,000. CrossGen Wealth LLC purchased a new stake in shares of IQVIA in the fourth quarter valued at about $28,000. Finally, Activest Wealth Management grew its position in IQVIA by 590.0% in the fourth quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock worth $31,000 after acquiring an additional 118 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.